GlaxoSmithKline's corporate venturing unit is now an independent firm with a $500m fund anchored by its former parent.
UK-headquartered pharmaceutical firm GlaxoSmithKline (GSK) spun off its corporate venturing unit, SR One, into an independent venture capital firm yesterday. GSK remains the largest investor in newly rebranded SR One Capital Management’s latest fund, an oversubscribed $500m vehicle also backed by undisclosed asset managers, pension funds, family offices, endowments and foundations. Founded in 1985, SR…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
